Company: XOMAP
Filing Date: 2025-08-18
Form Type: SC TO-T
Source: 0001193125-25-182241
Chunk: 3

Company: XOMA Royalty Corp
Filing Date: 2025-08-18
Form: SC TO-T
Chunk 3
---
 economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic drug candidates. The executive officers of Parent are
Owen Hughes, its Chief Executive Officer, Tom Burns, its Senior Vice President, Finance and Chief Financial Officer, Bradley Sitko, its Chief Investment Officer, and Maricel Montano, its Chief Legal Officer. Each executive officer of Parent is a
United States citizen and has a business address located at 2200 Powell Street, Suite 310, Emeryville, California 94608.

The information set forth in “The Tender Offer—Section 6. Certain Information Concerning Purchasers” and Schedule A—“Information Concerning Members of the Boards of Directors and the Executive Officers of Purchasers” of the Offer to Purchase is incorporated herein by reference.

| ITEM 4. | TERMS OF THE TRANSACTION. |

(a)(1)(i)-(viii), (x), (xii), (a)(2)(i)-(v), (vii) The information set forth in the Offer to Purchase is incorporated herein by reference. (a)(1)(ix), (xi), (a)(2)(vi) Not applicable.

| ITEM 5. | PAST CONTACTS, TRANSACTIONS, NEGOTIATIONS AND AGREEMENTS. |

(a), (b) The information set forth in “Special Factors—Section 1. Background of the Offer; Contacts with HilleVax,” “Special Factors—Section 2. Purpose of the Offer and Plans for HilleVax,” “The Tender Offer—Section 5. Certain Information Concerning HilleVax,” “The Tender Offer—Section 6. Certain Information Concerning Purchasers” and “Schedule A—Information Concerning Members of the Boards of Directors and the Executive Officers of Purchasers” of the Offer to Purchase is incorporated herein by reference.

| ITEM 6. | PURPOSES OF THE TRANSACTION AND PLANS OR PROPOSALS. |

(a), (c)(1)–(7) The information set forth in the sections of the Offer to Purchase titled “Summary Term Sheet” and “Introduction” and in “Special Factors—Section 2. Purpose of the Offer and Plans for HilleVax,” “Special Factors—Section 3. Price Range of Shares; Dividends,” “Special Factors—Section 4. Possible Effects of the Offer on the Market for the Shares; Nasdaq Listing; Exchange Act Registration and Margin Regulations,” “The Tender Offer—Section